Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.

Autor: Oluwole OO; Vanderbilt University Medical Cancer Center, Nashville, TN, USA. olalekan.oluwole@vumc.org., Forcade E; Service d'Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire de Bordeaux, F-33000, Bordeaux, France., Muñoz J; Banner MD Anderson Cancer Center, Gilbert, AZ, USA., de Guibert S; Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France., Vose JM; University of Nebraska Medical Center, Omaha, NE, USA., Bartlett NL; Washington University School of Medicine and Siteman Cancer Center, St Louis, MO, USA., Lin Y; Mayo Clinic, Rochester, MN, USA., Deol A; Karmanos Cancer Center, Wayne State University, Detroit, MI, USA., McSweeney P; Colorado Blood Cancer Institute, Denver, CO, USA., Goy AH; John Theurer Cancer Center, Hackensack, NJ, USA., Kersten MJ; Amsterdam UMC, Location University of Amsterdam, Cancer Center Amsterdam, Amsterdam (on behalf of HOVON/LLPC), The Netherlands., Jacobson CA; Dana-Farber Cancer Institute, Boston, MA, USA., Farooq U; University of Iowa, Iowa City, IA, USA., Minnema MC; University Medical Center Utrecht (on behalf of HOVON/LLPC), Utrecht, The Netherlands., Thieblemont C; Paris University, Assistance publique-Hôpitaux de Paris, Hemato-oncology, F-75010, Paris, France., Timmerman JM; University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA., Stiff P; Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA., Avivi I; Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Tzachanis D; University of California San Diego, La Jolla, CA, USA., Zheng Y; Kite, a Gilead Company, Santa Monica, CA, USA., Vardhanabhuti S; Kite, a Gilead Company, Santa Monica, CA, USA., Nater J; Kite, a Gilead Company, Santa Monica, CA, USA., Shen RR; Kite, a Gilead Company, Santa Monica, CA, USA., Miao H; Kite, a Gilead Company, Santa Monica, CA, USA., Kim JJ; Kite, a Gilead Company, Santa Monica, CA, USA., van Meerten T; University Medical Center Groningen, Groningen (on behalf of HOVON/LLPC), The Netherlands.
Jazyk: angličtina
Zdroj: Bone marrow transplantation [Bone Marrow Transplant] 2024 Mar; Vol. 59 (3), pp. 366-372. Date of Electronic Publication: 2024 Jan 04.
DOI: 10.1038/s41409-023-02169-z
Abstrakt: ZUMA-1 safety management cohort 6 investigated the impact of prophylactic corticosteroids and earlier corticosteroids and/or tocilizumab on the incidence and severity of cytokine release syndrome (CRS) and neurologic events (NEs) following axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Prior analyses of cohort 6 with limited follow-up demonstrated no Grade ≥3 CRS, a low rate of NEs, and high response rates, without negatively impacting axi-cel pharmacokinetics. Herein, long-term outcomes of cohort 6 (N = 40) are reported (median follow-up, 26.9 months). Since the 1-year analysis (Oluwole, et al. Blood. 2022;138[suppl 1]:2832), no new CRS was reported. Two new NEs occurred in two patients (Grade 2 dementia unrelated to axi-cel; Grade 5 axi-cel-related leukoencephalopathy). Six new infections and eight deaths (five progressive disease; one leukoencephalopathy; two COVID-19) occurred. Objective and complete response rates remained at 95% and 80%, respectively. Median duration of response and progression-free survival were reached at 25.9 and 26.8 months, respectively. Median overall survival has not yet been reached. Eighteen patients (45%) remained in ongoing response at data cutoff. With ≥2 years of follow-up, prophylactic corticosteroids and earlier corticosteroids and/or tocilizumab continued to demonstrate CRS improvement without compromising efficacy outcomes, which remained high and durable.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: